Skip to main content
. Author manuscript; available in PMC: 2021 Feb 1.
Published in final edited form as: Lancet Oncol. 2019 Dec 20;21(2):283–293. doi: 10.1016/S1470-2045(19)30797-1

Table 3:

Clinicopathologic characteristics of MSK immunotherapy cohort.

N=203
Age, mean (SD) 62 (13)
Male, n (%) 151 (74·0)
BMI, mean (SD) 26·9 (6·3)
BMI category, n (%)
 Normal 63 (31·0)
 Overweight 74 (36·5)
 Obese 66 (32·5)
IMDC risk group, n (%)
 Favorable 35 (17·9)
 Intermediate 128 (65·3)
 Poor 33 (16·8)
 Unknown 7
IO Treatment Line, n (%)
 First line 48 (23·6)
 ≥Second line 155 (76·4)

IO=immunotherapy. BMI=body mass index. SD=standard deviation.